ADMA Biologics Inc (NASDAQ:ADMA) Shares Purchased by Calamos Advisors LLC

Calamos Advisors LLC lifted its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 25.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 533,837 shares of the biotechnology company's stock after buying an additional 107,931 shares during the period. Calamos Advisors LLC owned approximately 0.22% of ADMA Biologics worth $10,591,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ADMA. B Group Inc. acquired a new position in ADMA Biologics in the fourth quarter valued at $39,231,000. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at about $19,076,000. Arrowstreet Capital Limited Partnership boosted its holdings in ADMA Biologics by 57.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock worth $47,380,000 after buying an additional 1,013,456 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after buying an additional 643,661 shares in the last quarter. Finally, Man Group plc boosted its holdings in ADMA Biologics by 305.5% during the fourth quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock worth $12,782,000 after buying an additional 561,507 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the topic of several recent research reports. Raymond James Financial upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

ADMA Biologics Stock Up 0.9%

NASDAQ ADMA traded up $0.16 during trading hours on Friday, reaching $18.30. 1,053,349 shares of the company traded hands, compared to its average volume of 3,708,646. ADMA Biologics Inc has a 12 month low of $10.21 and a 12 month high of $25.67. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $4.37 billion, a PE ratio of 21.52 and a beta of 0.43. The company has a 50 day moving average of $20.24 and a two-hundred day moving average of $18.73.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same quarter last year, the company earned $0.08 earnings per share. The company's revenue was up 40.2% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director owned 94,830 shares in the company, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,621 shares of company stock worth $9,644,269. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.